Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II booster trial of WSK-V102 recombinant variant COVID-19 vaccine
ChiCTR2300069278Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of recombinant COVID-19 variant vaccine in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Incidence of solicited adverse events within 14 days after vaccination and Geometric mean titer of neutralizing antibodies against SARS-CoV-2 prototype and Omicron variants. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
recombinant COVID-19 variant vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300069278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069278.